By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Figure out How to Get the Best Open Record Rewards - 2Volunteers aiding humpback whale stranded in Baltic get death threats
- 3Thyssenkrupp to suspend electrical steel production at French site
- 4Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- 5Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Merz: 80% of Syrians in Germany expected to return within three years
- Manual for Famous people Known for Their Altruistic Endeavors
- Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- Turning into a Distributed Writer: My Composing Process
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- Russia Creates New Military Branch Dedicated To Drone Warfare
- December’s full moon is the last supermoon of the year. Here’s what to know
